Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Population pharmacokinetic analysis of axitinib in healthy volunteers.

British journal of clinical pharmacology - 1 Mar 2014

Garrett May, Poland Bill, Brennan Meghan, Hee Brian, Pithavala Yazdi K, Amantea Michael A

Abstract excerpt

AIMS: Axitinib is a potent and selective second generation inhibitor of vascular endothelial growth factor receptors 1, 2 and 3 approved for second line treatment of advanced renal cell carcinoma. The objectives of this analysis were to assess plasma pharmacokinetics and identify covariates that may explain variability in axitinib disposition following single dose administration in healthy volunteers. METHODS:...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Angiogenesis Inhibitors
Share to Biotransformation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Clinical Trials, Phase I as Topic

Share to Drug Dosage Calculations

Share to Glucuronosyltransferase

Share to Healthy Volunteers

Share to Indazoles

Share to Nonlinear Dynamics

Source

Open in PubMed Open full text

Identifiers

PMID: 23834452
DOI: 10.1111/bcp.12206
PMCID: PMC3952722

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Population pharmacokinetic analysis of axitinib in healthy volunteers.PMID 23834452Read ↗

Effect of ketoconazole on the pharmacokinetics of axitinib in healthy volunteers.Semantic proximity Read ↗

Absorption of the orally active multikinase inhibitor axitinib as a therapeutic index to guide dose titration in metastatic renal cell carcinoma.Semantic proximity Read ↗

Association of axitinib plasma exposure and genetic polymorphisms of ABC transporters with axitinib-induced toxicities in patients with renal cell carcinoma.Semantic proximity Read ↗

In Vitro Kinetic Characterization of Axitinib Metabolism.Semantic proximity Read ↗

Effect of rifampin on the pharmacokinetics of Axitinib (AG-013736) in Japanese and Caucasian healthy volunteers.Semantic proximity Read ↗

Contribution of UGT1A1 genetic polymorphisms related to axitinib pharmacokinetics to safety and efficacy in patients with renal cell carcinoma.Semantic proximity Read ↗

Population Pharmacokinetic Modeling of Encorafenib in Healthy Participants and Patients with BRAF V600-Mutant Solid Tumors: A Semi-mechanistic Autoinduction Model.Semantic proximity Read ↗

Improving Understanding of Fexofenadine Pharmacokinetics to Assess Pgp Phenotypic Activity in Older Adult Patients Using Population Pharmacokinetic Modeling.Semantic proximity Read ↗

Population pharmacokinetics of ABT-767 in BRCA1 or BRCA2 mutation carriers with advanced solid tumors or in subjects with high grade serous ovarian, primary peritoneal or fallopian tube cancer.Semantic proximity Read ↗

Phase 1 study to investigate the pharmacokinetic properties of dacomitinib in healthy adult Chinese subjects genotyped for CYP2D6.Semantic proximity Read ↗

Phase 1 Dose-Escalation Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Tofacitinib in Japanese Healthy Volunteers.Semantic proximity Read ↗

Development of a predictive pharmacokinetic model for a novel cyclooxygenase-2 inhibitor.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.